血液与肠道:肠道微生物组如何塑造造血及血液病治疗
本文综述肠道微生物组与造血系统的相互作用,包括微生物代谢物经循环触发细胞因子信号影响稳态造血,以及微生物组状态影响造血干细胞移植、免疫治疗和细胞治疗结局,并提出未来研究方向。
要点
- 肠道微生物群影响稳态造血,作用于造血干/祖细胞及分化免疫细胞。
- 微生物代谢物入循环触发细胞因子信号,进而影响造血。
- 微生物组状态影响造血干细胞移植、免疫治疗和细胞治疗结局。
核心结论
- 肠道微生物组与造血系统存在相互作用,微生物组状态影响造血干细胞移植、免疫治疗和细胞治疗结局。
- 未来研究可能减少抗生素使用的不良反应并改善血液病患者结局。
研究设计与样本
- 综述,总结肠道微生物组影响发育期和成年期造血的机制,以及影响干细胞移植植入、移植物抗宿主病和细胞/免疫治疗疗效的途径。
主要发现
- 正常肠道微生物群影响稳态血液生成,作用于造血干/祖细胞及分化免疫细胞。
- 微生物代谢物进入循环,触发影响造血的细胞因子信号。
- 微生物组状态影响造血干细胞移植、免疫治疗和细胞治疗的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past 10 years, there has been a marked increase in recognition of the interplay between the intestinal microbiome and the hematopoietic system. Despite their apparent distance in the body, a large literature now supports the relevance of the normal intestinal microbiota to steady-state blood production, affecting both hematopoietic stem and progenitor cells as well as differentiated immune cells. Microbial metabolites enter the circulation where they can trigger cytokine signaling that influences hematopoiesis. Furthermore, the state of the microbiome is now recognized to affect outcomes from hematopoietic stem cell transplant, immunotherapy, and cellular therapies for hematologic malignancies. Here we review the mechanisms by which microbiotas influence hematopoiesis in development and adulthood as well as the avenues by which microbiotas are thought to impact stem cell transplant engraftment, graft-versus-host disease, and efficacy of cell and immunotherapies. We highlight areas of future research that may lead to reduced adverse effects of antibiotic use and improved outcomes for patients with hematologic conditions.
引用
- Fernandez Sanchez J, Maknojia AA, King KY, et al. Blood and guts: how the intestinal microbiome shapes hematopoiesis and treatment of hematologic disease. Blood. 2024. PMID: 38364184. doi:10.1182/blood.2023021174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。